

RECEIVED
JAN 15 2004
TECH CENTER 1600/2900

In the Claims

Please amend the claims as follows.

1. (Withdrawn) A pharmaceutical composition for the treatment or amelioration of central nervous system dependent conditions comprising (i) an effective amount of agmatine, an agmatine analog or a pharmaceutically acceptable salt thereof and (ii) a pharmaceutically acceptable carrier.


2. (Withdrawn) The pharmaceutical composition according to claim 1 comprising a dose of about 0.1 mg/kg to about 300 mg/kg of agmatine, an agmatine analog or a pharmaceutically acceptable salt thereof.

3. (Withdrawn) The pharmaceutical composition according to claim 1 comprising a dose of about 1 mg/kg to about 50 mg/kg of agmatine, or a pharmaceutically acceptable salt thereof.

4. (Withdrawn) The pharmaceutical composition according to claim 2 comprising saline as the pharmaceutical carrier.

5. (Currently amended) A method of treating, ameliorating, or preventing seizures associated with epilepsy, seizure, or electroconvulsive disorders in a subject in need thereof, the method comprising:

administering a pharmaceutical composition comprising an effective amount about 0.1 to about 500 mg of agmatine or an agmatine analog, or a pharmaceutically acceptable salt thereof per kilogram of the subject's weight of agmatine, an agmatine analog, or a pharmaceutically acceptable salt thereof to treat, reduce, or prevent the disorder seizures associated with epilepsy in the subject, wherein the agmatine analog has the following formula




wherein n is 0 to about 10;

R₁, R₂, R₃, R₄, and R₅, are each independently, or any combination thereof: hydrogen, hydroxy, substituted or unsubstituted C₁₋₁₀ alkyl, substituted or unsubstituted C₃₋₈ cycloalkyl, substituted or unsubstituted arylalkyl (comprising Ar-(CH₂)_m; where Ar is aromatic and m is 0 to about 10) substituted or unsubstituted C₁₋₁₀ alkoxy, substituted or unsubstituted C₁₋₁₀ acyl, halogeno, amido, phenyl, thio, or amino; and

X and Y are each independently: O, NH, CH₂, CF₂, Se, C=O, C=N, or C=S, or X-Y together is HC=CH, C≡C, N=N, N=CH, CH=N, or a saturated or unsaturated ring.

6. (Canceled herein). A method according to claim 5, wherein the agmatine or agmatine analog has the following formula



wherein n is 0 to about 10;

R₁, R₂, R₃, R₄, and R₅, are each independently, or any combination thereof: hydrogen, hydroxy, substituted or unsubstituted C₁₋₁₀ alkyl, substituted or unsubstituted C₃₋₈ cycloalkyl, substituted or unsubstituted arylalkyl (comprising Ar-(CH₂)_m; where Ar is aromatic and m is 0 to about 10) substituted or unsubstituted C₁₋₁₀ alkoxy, substituted or unsubstituted C₁₋₁₀ acyl, halogeno, amido, phenyl, thio, amino; and

X and Y are each independently: O, NH, CH₂, CF₂, Se, C=O, C=N, C=S, or S; or X-Y together is HC=CH, C≡C, N=N, N=CH, CH=N, or a saturated or unsaturated ring.

7. (Original) A method according to claim 5, wherein the pharmaceutical composition comprises agmatine or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier.

8. (Canceled herein) A method according to claim 5, wherein the composition is administered to a human subject in a dose of about 0.1 to about 500 mg of the agmatine or agmatine analog per kilogram of the human subject's weight.

9. (Currently amended) A method according to claim 8, wherein the composition is administered in a dose of about 0.1 to about 50 mg/kg per day indefinitely or until symptoms/seizures associated with the condition or disorder cease/epilepsy.

10. (Canceled herein). A method of treating the occurrence of epilepsy, seizure or electroconvulsive disorders in a human comprising the step of administering ~~an effective amount of agmatine, an agmatine analog or a pharmaceutically acceptable salt thereof~~ about 0.1 to about 500 mg of agmatine or an agmatine analog, or a pharmaceutically acceptable salt thereof per kilogram of the subject's weight to a human in need thereof and preventing or reducing the disorder.


11. (Currently amended) A method according to claim ~~405~~, comprising preventing or reducing seizure activity ~~as the disorder.~~

12. (Canceled herein) A method according to claim ~~405~~, comprising preventing or reducing epileptic activity as the disorder.

13. (Currently amended) A method of treating or preventing seizures associated with ~~epilepsy-seizure or electroconvulsive disorders~~ in a human comprising:

identifying a human subject in need of said treatment or prevention; and

administering ~~an effective amount of agmatine, an agmatine analog or a pharmaceutically acceptable salt thereof~~ about 0.1 to about 500 mg of agmatine or an agmatine analog , or a pharmaceutically acceptable salt thereof per kilogram of the subject's weight to the human subject, wherein the agmatine analog has the following formula



wherein n is 0 to about 10;

R₁, R₂, R₃, R₄, and R₅, are each independently, or any combination thereof: hydrogen, hydroxy, substituted or unsubstituted C₁₋₁₀ alkyl, substituted or unsubstituted C₃₋₈ cycloalkyl, substituted or unsubstituted arylalkyl (comprising Ar-(CH₂)_m; where Ar is aromatic and m is 0 to about 10) substituted or unsubstituted C₁₋₁₀ alkoxy, substituted or unsubstituted C₁₋₁₀ acyl, halogeno, amido, phenyl, thio, or amino; and

X and Y are each independently: O, NH, CH₂, CF₂, Se, C=O, C=N, or C=S, or X-Y together is HC=CH, C≡C, N=N, N=CH, CH=N, or a saturated or unsaturated ring.

14. (Original) A method according to claim 13, comprising identifying a human subject in need of said treatment by analyzing an electroencephalogram taken of the human subject.

15. (Currently amended) A method according to claim 13, comprising identifying a human subject in need of said treatment by observing ~~one or more features associated with the~~ occurrence of a seizure in said subject.

16. (Currently amended). A method according to claim 13, comprising administering the effective amount of agmatine, an agmatine analog or a pharmaceutically acceptable salt thereof

to the human subject indefinitely or until the ~~symptoms or features associate with the disorder~~ seizures associated with epilepsy cease.

17. (Currently amended) A method according to claim 13, comprising preventing or reducing seizures associated with epileptic activity ~~as the disorder~~.

18. (Original) A method according to claim 13, comprising administering the effective amount of agmatine, an agmatine analog or a pharmaceutically acceptable salt thereof as a pharmaceutical composition.

19. (Original) A method according to claim 13, comprising administering the effective amount of agmatine, an agmatine analog or a pharmaceutically acceptable salt thereof parenterally.

20. (Original). A method according to claim 13, comprising administering the effective amount of agmatine, an agmatine analog or a pharmaceutically acceptable salt thereof orally.